Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hélène Bugaut, Mélanie Bruchard, Hélène Berger, Valentin Derangère, Ludivine Odoul, Romain Euvrard, Sylvain Ladoire, Fanny Chalmin, Frédérique Végran, Cédric Rébé, Lionel Apetoh, François Ghiringhelli, Grégoire Mignot
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c

Ejemplares similares